BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Oct 23, 2025 • 9min
Weave Bio, which raised a $20M series A this month, is aiming to use software and LLMs to automate and streamline regulatory submissions for drug development
Co-Founder & CEO Brandon Rice says that in one project it worked on with a pharma, Weave's technology took only 3 hours to draft regulatory documents what would have taken humans to 100 hours.
Oct 22, 2025 • 21min
Ahead of a year of increased clinical activity, Entrada Therapeutics' CEO Dipal Doshi discusses the company's EEV platform, DMD programs, and a Vertex partnership in DM1
He walks us through exon 44 and 45 programs, which will both likely have clinical readouts in 2026. Meanwhile, a $350M cash position gives Entrada the ability to think beyond neuromuscular conditions in the future as well.
Oct 22, 2025 • 23min
Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)
He describes how Disc applied for and was awarded a CNPV for Bitopertin, which treats a rare disease that causes extreme sensitivity to sunlight. Plus, quickly ramping up a commercial team, and discussing Disc's two other development programs.
Oct 22, 2025 • 52min
Biotech entrepreneurs share advice on navigating through today's uncertain times: "It's going to be okay"
MassBio CEO Kendalle Burlin O'Connell moderates a discussion with Normunity CEO Rachel Humphrey and Gallop Oncology CEO Luba Greenwood about how they are rising to today's challenges. Topics include the funding environment, motivating your team, storytelling, FDA Engagement, and perseverance.
6 snips
Oct 22, 2025 • 10min
Flagship Pioneering announced its newest company to emerge out of stealth mode today: Expedition Medicines. It is leveraging generative design for small molecule covalent chemistry
Molly Gibson, Co-founder and CEO of Expedition Medicines, dives into the innovative world of generative covalent small-molecule chemistry. She explains how her company is revolutionizing drug development with a $50 million backing and a partnership with Pfizer to tackle challenging targets like prostate cancer. Listeners will learn about the technology behind covalent chemistry, real-world applications, and the use of AI to generate new drug candidates. Molly also highlights Expedition's unique approach compared to other biotech firms, emphasizing their focus on previously undrugged targets.
Oct 21, 2025 • 15min
Biotech veteran Oz Azam has become the CEO of Cue Biopharma. He walks us through the science behind the company's new focus in autoimmune that has him excited about the opportunity
He describes CUE-401, which combines a TGF-beta breathing-mask moiety with an interleukin (IL-2) mutein, and CUE-501, a Boehringer Ingelheim partnered program which is designed to deplete B-cells by painting them and engaging with virus-specific memory T-cells.
Oct 21, 2025 • 15min
Get to know Women In Bio, and how this organization helps women at all stages of their careers in biotech
During a meeting in Boston at Portal Innovations where Women in Bio (WIB) was working on its 'Boardroom Ready' initiative, Dianne Keen-Kim (National President and Board Chair), Gina Ford (CEO), and Katherine Andersen (Board Member) discuss how WIB helps women in our industry today and its goals for the future.
Oct 16, 2025 • 21min
Emeryville, CA based Profusa is developing an injectable biosensor that aims to generate biochemistry information for users in real time
Chairman & CEO Ben Hwang describes the idea behind Profusa's approach, and how he believes it delivers more robust and actionable information than purely surface based tools such as the Apple Watch.
Oct 15, 2025 • 25min
PepGen's CEO James McArthur gives an overview of the company's recent data in myotonic dystrophy type 1, which showed a mean splicing correction of 53.7% at the 15 mg/kg dose
He describes the science behind PepGen's "Enhanced Delivery Oligonucleotide (EDO)" platform, and explain how he believes it gives the company a differentiated advantage in this condition by focusing on the pathogenic repeat that causes DM1 and restoring normal function.
Oct 14, 2025 • 8min
Benchtalk 2025: Kate Haviland discusses the $9B+ acquisition of Blueprint by Sanofi, being chair of Fulcrum, her thoughts on M&A, and what is interesting in biotech today
The CEO of Blueprint (up to the acquisition) discusses the company's success factors, and being led to immunology by the science. Plus, why she believes an oral pill that is disease modifying, like Fulcrum is trying to develop, is strongly needed for the sickle cell patient community.
